KCM
SAGE

Kingdon Capital Management’s Sage Therapeutics SAGE Stock Holding History

Kingdon Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200,000
Closed -$10.2M – 136
2016
Q4 		$10.2M Buy
+200,000
New +$9.43M 0.49% 62
2016
Q3 		– Sell
-300,000
Closed -$9.04M – 132
2016
Q2 		$9.04M Buy
+300,000
New +$10M 0.5% 54

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Kingdon Capital Management's SAGE Position: Q1 2019 in Review

Kingdon Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 146,179 shares — an estimated $14M sold.

Kingdon Capital Management first reported a position in SAGE in Q2 2016 and held it in 6 quarters. The position peaked at $23.3M in Q3 2016. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • Kingdon Capital Management reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Kingdon Capital Management sold 146,179 Sage Therapeutics shares in Q1 2019, an estimated $14M.
  • Kingdon Capital Management first reported a position in Sage Therapeutics in Q2 2016 and held it in 6 quarters.
  • Kingdon Capital Management's Sage Therapeutics position peaked at $23.3M in Q3 2016.
  • 268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Kingdon Capital Management's 13F filing for Q1 2019, filed 14 May 2019.